Olaparib When You Have — Other Health Conditions or Are Older

Yes, in many cases. Age alone does not determine whether olaparib is appropriate for you. What your oncologist looks at is how well your kidneys work, what your blood counts show, what other medicines you take, and how you are functioning day to day. Many people in their 70s and beyond take olaparib without serious problems. Your team will review all of these before you start and may check your blood tests more often than they would for a younger, otherwise healthy person.

Your oncologist will likely reduce the dose before you start, rather than beginning at the standard amount and waiting to see how you respond. How much it is reduced depends on how significantly your kidney function is affected. Mild impairment usually requires no change. More significant impairment does, and your oncologist will explain exactly what that means for your situation. Severe kidney impairment is an area where clinical data is more limited, so that conversation will need to happen carefully before you begin.

Yes, diabetes alone does not rule out olaparib. Most medicines used for diabetes do not interact significantly with olaparib. What your team will watch is any impact on your appetite and blood sugar management, since nausea from olaparib can make eating regularly harder. Tell your diabetes team or family doctor that you are starting olaparib, so they are aware if your blood sugar control changes during the first few weeks of treatment.

Most common blood pressure medicines do not interact significantly with olaparib. The medicines that matter most are those that affect a liver enzyme called CYP3A — these include certain antifungals, some TB antibiotics, some epilepsy medicines, and some HIV medicines, rather than the most common blood pressure treatments. Still, bring your complete medicine list to every appointment, because some less common blood pressure drugs do affect this enzyme and your team will need to check.

Low counts from previous treatment do not automatically rule olaparib out, but your team may want your counts to recover to a safe level before you begin. Once you start, blood tests are likely to be checked more often than they would be for someone starting with normal counts. Tell your oncologist exactly what chemotherapy you had and when, because how recently it was matters as much as what it was.

It can, and knowing this in advance helps. Fatigue is one of the most common side effects of olaparib. If you are already tired from anaemia, from the cancer itself, or from a previous treatment, the added tiredness may feel more significant. Tell your team if fatigue is affecting what you can manage day to day — it is not something you are expected to push through. Checking your blood counts is usually the first step, because anaemia is often what is driving it.

Olaparib is not known to cause the kind of heart rhythm problems that some other cancer medicines do. If you have a heart condition, tell your oncologist and share your full list of heart medicines before starting. Severe anaemia from olaparib can put extra strain on the heart, so blood counts will be watched carefully. If breathlessness or chest discomfort increases after you start, tell your team promptly rather than waiting for your next scheduled appointment.

Tell your oncologist what you are taking before making any decisions about stopping or continuing. Some herbal preparations interact with olaparib — St John's Wort is the most well-documented example and can significantly reduce olaparib levels in your blood. Many other herbal and Ayurvedic medicines have not been specifically studied alongside olaparib, meaning the risk is unknown rather than confirmed safe. Tell your treating team what you are using at every appointment, and do not stop anything on your own without discussing it first.